Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial

JCI Insight
Nan JiZhixian Gao

Abstract

Heat shock protein peptide complex-96 (HSPPC-96) triggers adaptive and innate antitumor immune responses. The safety and efficacy of HSPPC-96 vaccination was examined in patients with newly diagnosed glioblastoma multiforme (GBM). In this open-label, single-arm, phase I study, adult patients were vaccinated with HSPPC-96 in combination with the standard treatment for newly diagnosed GBM after surgical resection. Primary endpoints were frequency of adverse events and progression-free survival (PFS) at 6 months. Secondary endpoints included overall survival (OS), PFS, and tumor-specific immune response (TSIR). A total of 20 patients with newly diagnosed GBM were enrolled from September 2013 to February 2015. No grade 3 or 4 vaccine-related adverse events were noted. After a median follow-up of 42.3 months, PFS was 89.5% (95% CI, 66.9%-98.7%) at 6 months, median PFS was 11.0 months (95% CI, 8.2-13.8), and median OS was 31.4 months (95% CI, 14.9-47.9). TSIR was significantly increased by 2.3-fold (95% CI, 1.7-3.2) after vaccination. Median OS for patients with high TSIR after vaccination was >40.5 months (95% CI, incalculable) as compared with 14.6 months (95% CI, 7.0-22.2) for patients with low TSIR after vaccination (hazard ratio...Continue Reading

References

Dec 12, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·H ZhengZ Li
Aug 23, 2002·Journal of Immunological Methods·Song-Dong MengGeorge F Gao
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Feb 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alessandro TestoriUNKNOWN C-100-21 Study Group
Mar 17, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenSusan M Chang
Jul 27, 2011·Cancer Immunology, Immunotherapy : CII·Xiaoli YanSongdong Meng
Aug 9, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Courtney A CraneAndrew T Parsa
Jun 11, 2014·Nature Reviews. Neurology·Wolfgang WickGuido Reifenberger
Sep 6, 2014·Neuro-oncology·David A ReardonGlenn Dranoff
Feb 5, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Debraj GuhaThakurtaCharles G Drake
Jul 19, 2015·Neuro-oncology·Matthew S WaitkusHai Yan
Oct 31, 2015·Neuro-oncology·Edjah K NduomAmy B Heimberger
Mar 12, 2016·Nature Reviews. Drug Discovery·Axel Hoos
Oct 16, 2016·Journal of Neuro-oncology·Amanda TivnanJochen H M Prehn
Dec 27, 2016·Biochemical Pharmacology·Davide ManganiPatrick Roth
Jan 5, 2017·Clinical and Translational Medicine·Gabriele D'ErricoBruno Sainz
Apr 24, 2017·Journal of Neuro-oncology·Anna C Filley, Mahua Dey
May 13, 2017·Nature Reviews. Neurology·Michael WellerJohn H Sampson
Jun 24, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John H SampsonCarl H June

❮ Previous
Next ❯

Citations

May 12, 2020·Neuro-oncology·Maryam RahmanDavid A Reardon
Oct 13, 2018·Current Treatment Options in Oncology·Lan B Hoang-Minh, Duane A Mitchell
Nov 23, 2019·International Journal of Molecular Sciences·Rebeca Piatniczka IglesiaMarilene Hohmuth Lopes
Sep 15, 2020·Chinese Neurosurgical Journal·Chunzhao LiNan Ji
Oct 6, 2020·Neuro-oncology Practice·Megan L MontoyaHideho Okada
Aug 14, 2019·Current Opinion in Oncology·Valérie DutoitPierre-Yves Dietrich
Mar 7, 2021·Cancers·Hong-My NguyenDipongkor Saha
Mar 7, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Shalini Sundramurthi ChelliahIshwar Parhar
Mar 31, 2021·Neurosurgery Clinics of North America·Justin LeeLinda M Liau
May 1, 2021·International Journal of Molecular Sciences·Sanjeev ChawlaHarish Poptani
May 28, 2021·Frontiers in Oncology·Stephen C FredericoMasaki Terabe
Jul 16, 2020·Current Drug Metabolism·Elmira MohtashamiAmir R Afshari
Jun 15, 2021·Frontiers in Neuroscience·Eduard YakubovHans-Herbert Steiner
Jul 25, 2021·Cancers·Chirayu R ChokshiSheila K Singh
Sep 3, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Sumbal RasheedMuhammad Sajid Hamid Akash
Oct 31, 2021·Journal of Hematology & Oncology·Yang XunHua You

❮ Previous
Next ❯

Methods Mentioned

BETA
PMA

Clinical Trials Mentioned

NCT02122822

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.